A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults
Thirteen multinational, Phase III studies were conducted to establish the efficacy of telithromycin 800 mg once daily in the treatment of community-acquired respiratory tract infections (RTIs). Data were analyzed from 4,743 adult patients participating across four indications: community-acquired pne...
Gespeichert in:
| Veröffentlicht in: | Infection 2003-10, Vol.31 (5), p.308-317 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 317 |
|---|---|
| container_issue | 5 |
| container_start_page | 308 |
| container_title | Infection |
| container_volume | 31 |
| creator | CARBON, C |
| description | Thirteen multinational, Phase III studies were conducted to establish the efficacy of telithromycin 800 mg once daily in the treatment of community-acquired respiratory tract infections (RTIs).
Data were analyzed from 4,743 adult patients participating across four indications: community-acquired pneumonia (CAP) of mild to moderate severity, acute exacerbations of chronic bronchitis (AECB), acute maxillary sinusitis (AMS) and tonsillitis/pharyngitis.
Treatment with telithromycin for either 5 days (AECB, AMS and tonsillitis/pharyngitis) or 7-10 days (CAP and AMS) provided high rates of clinical and bacteriologic cure (5-day, 87.0% and 86.0%, respectively; 7 to 10-days, 90.3% and 90.5%, respectively) that were equivalent to those of a 10-day course of comparator antibacterials (86.5% and 86.5%, respectively). The clinical efficacy of telithromycin extended to high-risk CAP and AECB patients and to all key respiratory pathogens, including Streptococcus pneumoniae strains resistant to penicillin or erythromycin and atypical/intracellular pathogens. Telithromycin was generally well-tolerated across patient groups.
These findings support the use of telithromycin as an effective therapy for the treatment of community-acquired RTIs. |
| doi_str_mv | 10.1007/s15010-003-3142-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71255449</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>697217671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-81ec6dbc626da7f4dc35de881956b0635879199fa70a04e7b52407bd6a868de83</originalsourceid><addsrcrecordid>eNpdkc1q3TAQRkVoSW7SPkA3xRSandsZ689ehtCkhUA37VrIskwUbMvRyAu_fXW5FwIFwYA432GYj7FPCN8QQH8nlIBQA_Cao2hqvGAHFLyrodP8HTsAB6hbbNQVuyZ6AQDZCX3JrlBIqUDKA1vvqjXGyQ-VXey0U6AqjlX2U8jPKc67C0tVXn72VU7e5tkv-Ui4OM_bEvJeW_e6hVQEydMaks0x7YW1Lpfg6F0OcaGjww7blOkDez_aifzH87xhfx9-_Ln_WT_9fvx1f_dUOy5FLlt7p4beqUYNVo9iKN-Db1vspOpBcdnqDrtutBosCK972QjQ_aBsq9oC8ht2e_KuKb5unrKZAzk_TXbxcSOjsZFSiK6AX_4DX-KWyjHINCgVtkVYIDxBLkWi5EezpjDbtBsEc-zCnLowpQtz7MJgyXw-i7d-9sNb4nz8Anw9A5acncZkFxfojZOoBBeK_wMM5ZLC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>215618868</pqid></control><display><type>article</type><title>A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>CARBON, C</creator><creatorcontrib>CARBON, C</creatorcontrib><description>Thirteen multinational, Phase III studies were conducted to establish the efficacy of telithromycin 800 mg once daily in the treatment of community-acquired respiratory tract infections (RTIs).
Data were analyzed from 4,743 adult patients participating across four indications: community-acquired pneumonia (CAP) of mild to moderate severity, acute exacerbations of chronic bronchitis (AECB), acute maxillary sinusitis (AMS) and tonsillitis/pharyngitis.
Treatment with telithromycin for either 5 days (AECB, AMS and tonsillitis/pharyngitis) or 7-10 days (CAP and AMS) provided high rates of clinical and bacteriologic cure (5-day, 87.0% and 86.0%, respectively; 7 to 10-days, 90.3% and 90.5%, respectively) that were equivalent to those of a 10-day course of comparator antibacterials (86.5% and 86.5%, respectively). The clinical efficacy of telithromycin extended to high-risk CAP and AECB patients and to all key respiratory pathogens, including Streptococcus pneumoniae strains resistant to penicillin or erythromycin and atypical/intracellular pathogens. Telithromycin was generally well-tolerated across patient groups.
These findings support the use of telithromycin as an effective therapy for the treatment of community-acquired RTIs.</description><identifier>ISSN: 0300-8126</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-003-3142-1</identifier><identifier>PMID: 14556055</identifier><identifier>CODEN: IFTNAL</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Acute Disease ; Adolescent ; Adult ; Aged ; Bacterial Infections - drug therapy ; Bacterial Infections - microbiology ; Biological and medical sciences ; Chronic obstructive pulmonary disease, asthma ; Clinical Trials, Phase III as Topic ; Community involvement ; Community-Acquired Infections - drug therapy ; Community-Acquired Infections - microbiology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Ketolides ; Macrolides - administration & dosage ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Middle Aged ; Multicenter Studies as Topic ; Non tumoral diseases ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; Pathogens ; Pneumology ; Randomized Controlled Trials as Topic ; Respiratory tract ; Respiratory Tract Infections - drug therapy ; Respiratory Tract Infections - microbiology ; Retrospective Studies ; Risk Assessment ; Treatment Outcome</subject><ispartof>Infection, 2003-10, Vol.31 (5), p.308-317</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Springer-Verlag 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-81ec6dbc626da7f4dc35de881956b0635879199fa70a04e7b52407bd6a868de83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15164346$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14556055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CARBON, C</creatorcontrib><title>A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults</title><title>Infection</title><addtitle>Infection</addtitle><description>Thirteen multinational, Phase III studies were conducted to establish the efficacy of telithromycin 800 mg once daily in the treatment of community-acquired respiratory tract infections (RTIs).
Data were analyzed from 4,743 adult patients participating across four indications: community-acquired pneumonia (CAP) of mild to moderate severity, acute exacerbations of chronic bronchitis (AECB), acute maxillary sinusitis (AMS) and tonsillitis/pharyngitis.
Treatment with telithromycin for either 5 days (AECB, AMS and tonsillitis/pharyngitis) or 7-10 days (CAP and AMS) provided high rates of clinical and bacteriologic cure (5-day, 87.0% and 86.0%, respectively; 7 to 10-days, 90.3% and 90.5%, respectively) that were equivalent to those of a 10-day course of comparator antibacterials (86.5% and 86.5%, respectively). The clinical efficacy of telithromycin extended to high-risk CAP and AECB patients and to all key respiratory pathogens, including Streptococcus pneumoniae strains resistant to penicillin or erythromycin and atypical/intracellular pathogens. Telithromycin was generally well-tolerated across patient groups.
These findings support the use of telithromycin as an effective therapy for the treatment of community-acquired RTIs.</description><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - microbiology</subject><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Community involvement</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Community-Acquired Infections - microbiology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Ketolides</subject><subject>Macrolides - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic</subject><subject>Non tumoral diseases</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Pathogens</subject><subject>Pneumology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Respiratory tract</subject><subject>Respiratory Tract Infections - drug therapy</subject><subject>Respiratory Tract Infections - microbiology</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Treatment Outcome</subject><issn>0300-8126</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkc1q3TAQRkVoSW7SPkA3xRSandsZ689ehtCkhUA37VrIskwUbMvRyAu_fXW5FwIFwYA432GYj7FPCN8QQH8nlIBQA_Cao2hqvGAHFLyrodP8HTsAB6hbbNQVuyZ6AQDZCX3JrlBIqUDKA1vvqjXGyQ-VXey0U6AqjlX2U8jPKc67C0tVXn72VU7e5tkv-Ui4OM_bEvJeW_e6hVQEydMaks0x7YW1Lpfg6F0OcaGjww7blOkDez_aifzH87xhfx9-_Ln_WT_9fvx1f_dUOy5FLlt7p4beqUYNVo9iKN-Db1vspOpBcdnqDrtutBosCK972QjQ_aBsq9oC8ht2e_KuKb5unrKZAzk_TXbxcSOjsZFSiK6AX_4DX-KWyjHINCgVtkVYIDxBLkWi5EezpjDbtBsEc-zCnLowpQtz7MJgyXw-i7d-9sNb4nz8Anw9A5acncZkFxfojZOoBBeK_wMM5ZLC</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>CARBON, C</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20031001</creationdate><title>A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults</title><author>CARBON, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-81ec6dbc626da7f4dc35de881956b0635879199fa70a04e7b52407bd6a868de83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - microbiology</topic><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Community involvement</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Community-Acquired Infections - microbiology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Ketolides</topic><topic>Macrolides - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic</topic><topic>Non tumoral diseases</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Pathogens</topic><topic>Pneumology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Respiratory tract</topic><topic>Respiratory Tract Infections - drug therapy</topic><topic>Respiratory Tract Infections - microbiology</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CARBON, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CARBON, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults</atitle><jtitle>Infection</jtitle><addtitle>Infection</addtitle><date>2003-10-01</date><risdate>2003</risdate><volume>31</volume><issue>5</issue><spage>308</spage><epage>317</epage><pages>308-317</pages><issn>0300-8126</issn><eissn>1439-0973</eissn><coden>IFTNAL</coden><abstract>Thirteen multinational, Phase III studies were conducted to establish the efficacy of telithromycin 800 mg once daily in the treatment of community-acquired respiratory tract infections (RTIs).
Data were analyzed from 4,743 adult patients participating across four indications: community-acquired pneumonia (CAP) of mild to moderate severity, acute exacerbations of chronic bronchitis (AECB), acute maxillary sinusitis (AMS) and tonsillitis/pharyngitis.
Treatment with telithromycin for either 5 days (AECB, AMS and tonsillitis/pharyngitis) or 7-10 days (CAP and AMS) provided high rates of clinical and bacteriologic cure (5-day, 87.0% and 86.0%, respectively; 7 to 10-days, 90.3% and 90.5%, respectively) that were equivalent to those of a 10-day course of comparator antibacterials (86.5% and 86.5%, respectively). The clinical efficacy of telithromycin extended to high-risk CAP and AECB patients and to all key respiratory pathogens, including Streptococcus pneumoniae strains resistant to penicillin or erythromycin and atypical/intracellular pathogens. Telithromycin was generally well-tolerated across patient groups.
These findings support the use of telithromycin as an effective therapy for the treatment of community-acquired RTIs.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>14556055</pmid><doi>10.1007/s15010-003-3142-1</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8126 |
| ispartof | Infection, 2003-10, Vol.31 (5), p.308-317 |
| issn | 0300-8126 1439-0973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71255449 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Acute Disease Adolescent Adult Aged Bacterial Infections - drug therapy Bacterial Infections - microbiology Biological and medical sciences Chronic obstructive pulmonary disease, asthma Clinical Trials, Phase III as Topic Community involvement Community-Acquired Infections - drug therapy Community-Acquired Infections - microbiology Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Humans Ketolides Macrolides - administration & dosage Male Medical sciences Microbial Sensitivity Tests Middle Aged Multicenter Studies as Topic Non tumoral diseases Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Pathogens Pneumology Randomized Controlled Trials as Topic Respiratory tract Respiratory Tract Infections - drug therapy Respiratory Tract Infections - microbiology Retrospective Studies Risk Assessment Treatment Outcome |
| title | A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T17%3A07%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20pooled%20analysis%20of%20telithromycin%20in%20the%20treatment%20of%20community-acquired%20respiratory%20tract%20infections%20in%20adults&rft.jtitle=Infection&rft.au=CARBON,%20C&rft.date=2003-10-01&rft.volume=31&rft.issue=5&rft.spage=308&rft.epage=317&rft.pages=308-317&rft.issn=0300-8126&rft.eissn=1439-0973&rft.coden=IFTNAL&rft_id=info:doi/10.1007/s15010-003-3142-1&rft_dat=%3Cproquest_cross%3E697217671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=215618868&rft_id=info:pmid/14556055&rfr_iscdi=true |